Skip to search formSkip to main contentSkip to account menu

ALT-801

Known as: IL-2 Recombinant Fusion Protein ALT-801 
A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Interleukin-2Recombinant Fusion ProteinsT-Cell Receptor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies.
3040 Background: ALT-801 is recombinant human interleukin-2 (IL-2) genetically fused to a single-chain T-cell receptor specific… 
2015
2015
Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder…
451 Background: Novel agents are necessary to treat BCG-resistant NMIBC to avoid radical cystectomy (RC). This phase I clinical… 
2015
2015
Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).
4515 Background: Although UC is sensitive to platinum-based chemotherapy such as gemcitabine (G) + cisplatin (C), patients who… 
2014
2014
Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells
ALT-801, a fusion of interleukin-2 and a single-chain T cell receptor domain specific to a p53 peptide/HLA-A*0201 complex, has… 
2013
2013
Phase I/II clinical trial of ALT-801, a T-cell receptor/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer.
271 Background: ALT-801, a T-cell receptor/IL-2 fusion protein, activates NK and CD4+ lymphocytes to secrete IFN-gamma which re… 
2012
2012
Intravenous administration of a novel IL-2 fusion protein, ALT-801, inhibits bladder cancer in mouse models (46.35)
ALT-801 is a fusion protein between interleukin-2 and a T cell receptor domain capable of recognizing tumors presenting human… 
Highly Cited
2011
Highly Cited
2011
Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
Purpose: ALT-801 is a bifunctional fusion protein comprising interleukin-2 (IL-2) linked to a soluble, single-chain T-cell… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)